| アブストラクト | PURPOSE: The oral corticosteroid (OCS)-sparing effect of several biologics (BIOs) has been shown in clinical trials. To date, no study has evaluated differences in OCS dose reduction between BIO-initiated and BIO-non-initiated patients in real-world clinical practice. We compared dose reductions in maintenance OCS between BIO-initiated and BIO-non-initiated severe asthma patients in a real-world setting. PATIENTS AND METHODS: This retrospective cohort study used the data from the Diagnosis Procedure Combination database of Medical Data Vision in Japan. Severe asthma patients with continuous use of OCS were selected from December 2015 to February 2020. The primary endpoint was the proportion reduction in daily maintenance OCS dose from Week 0 to Week 24. Analyses were performed using inverse probability treatment weighting. RESULTS: In total, 2927 patients were included (BIO-initiated: 239 patients, BIO-non-initiated: 2688 patients). Adjusted median (quartile [Q] 1-Q3) proportion reduction in daily maintenance OCS dose at Week 24 from the index date was 25.0% (0.0-100.0%) and 0.0% (0.0-83.3%) in the BIO-initiated and BIO-non-initiated groups, respectively (Hodges-Lehmann estimate [95% confidence interval], 0.0000% [0.0000-0.3365%]). Respective proportions of patients in the BIO-initiated and BIO-non-initiated groups achieving dose reductions from the index date in the daily maintenance OCS dose at Week 24 were >0% reduction, 56.6% and 44.1% (odds ratio [OR] 1.6554); >/=25% reduction, 50.5% and 40.6% (OR 1.4888); >/=50% reduction, 42.8% and 33.7% (OR 1.4714); and 100% reduction, 26.2% and 24.4% (OR 1.1005). CONCLUSION: Among severe asthma patients, the daily dose of maintenance OCS was reduced with BIO treatment. Although a higher percentage of patients in the BIO-initiated group had an OCS reduction of </=75% than the BIO-non-initiated group, we found no clear difference in OCS reduction. Our findings will be justified by further research that incorporates a longer observation period and variables excluded from this study. TRIAL REGISTRATION: ClinicalTrials.gov (NCT05136547). |
|---|
| ジャーナル名 | Journal of asthma and allergy |
|---|
| Pubmed追加日 | 2023/8/21 |
|---|
| 投稿者 | Tanaka, Akihiko; Takahashi, Mai; Fukui, Ayako; Arita, Yoshifumi; Fujiwara, Masakazu; Makita, Naoyuki; Tashiro, Naoki |
|---|
| 組織名 | Division of Respiratory Medicine and Allergology, Department of Medicine, School;of Medicine, Showa University, Tokyo, Japan.;Medical, AstraZeneca K.K., Tokyo, Japan.;Medical, AstraZeneca K.K., Osaka, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37600852/ |
|---|
